Research peptide head to head

CJC-1295 vs Sermorelin

Both are GHRH (growth-hormone-releasing hormone) analogues studied in preclinical literature. Sermorelin is the older, unmodified N-terminal fragment with a very short half-life. CJC-1295 is the newer tetra-substituted analogue, optionally bound to a DAC (Drug Affinity Complex) for albumin attachment that extends half-life dramatically. Neither has a UK marketing authorisation as a medicine. UK retailers sell both as research use only.

AI-friendly summary · CJC-1295 vs Sermorelin

CJC-1295 and Sermorelin are both GHRH (growth-hormone-releasing hormone) analogues studied in preclinical literature. Sermorelin is the older, unmodified N-terminal fragment with a very short half-life. CJC-1295 is the newer tetra-substituted analogue, optionally bound to a DAC (Drug Affinity Complex) that extends half-life dramatically through albumin attachment. Neither holds a UK marketing authorisation as a medicine, and UK retailers sell both research-use-only. PeptideClear publishes no dosing or human-use protocols for either.

	CJC-1295	Sermorelin
Class	GHRH analogue	GHRH analogue
Amino acids	30 (DAC variant 30 + DAC link)	29
Half-life	Approx 30 min (no DAC); 8+ days (with DAC)	Approx 10 to 20 minutes
Structural modification	Tetra-substituted, optional DAC for albumin binding	Unmodified N-terminal fragment of human GHRH
Discovery / origin	Conjuchem (mid-2000s)	Salk Institute (1970s); marketed as Geref by Serono
UK regulatory status	No marketing authorisation; research use only	No marketing authorisation; research use only
Often paired with	Ipamorelin	Ipamorelin
Typical CoA emphasis	DAC verification critical	Standard HPLC

Cross-reference: Sermorelin encyclopedia · best UK Sermorelin retailers.

Frequently asked questions

What's the main difference between CJC-1295 and Sermorelin?

Both are GHRH (growth-hormone-releasing hormone) analogues studied in preclinical literature. Sermorelin is the older, unmodified 29-amino-acid N-terminal fragment of human GHRH with a short half-life of 10 to 20 minutes. CJC-1295 is a newer tetra-substituted 30-amino-acid analogue, optionally bound to a DAC (Drug Affinity Complex) that extends half-life to roughly 8 days.

Which is more relevant in current research literature?

Sermorelin (originally marketed as Geref by Serono) was developed at the Salk Institute in the 1970s and has the longer publication history. CJC-1295 from Conjuchem is the newer molecule and most current preclinical interest centres on its DAC-bound long-half-life variant. Both are commonly paired with Ipamorelin in preclinical work.

Are both legal in the UK?

Neither CJC-1295 nor Sermorelin holds a UK marketing authorisation as a medicine. UK retailers sell both under "research use only, not for human or animal consumption" framing. Neither is a controlled drug under the Misuse of Drugs Act 1971.

Where can I buy CJC-1295 and Sermorelin in the UK?

Both are stocked by UK research peptide retailers including my-peptides, Pure Peptides UK, Direct Sarms, Aquila, Pinnacle, and Nooku. For CJC-1295, retailer DAC verification on the CoA is the key quality check.

Which has more human RCT data?

Neither has current published phase II or phase III human RCT data in the public domain. Sermorelin has a longer historical record from its time as Geref. CJC-1295 has no comparable approval history. The current research literature for both is overwhelmingly preclinical.

Ready to buy

Shop UK peptides, collagen and GLP-1 routes

Compare UK retailers, clinics and pharmacies across every PeptideClear category.

Shop UK products Find a UK clinic

CJC-1295 vs Sermorelin

Frequently asked questions

Shop UK peptides, collagen and GLP-1 routes

Related on PeptideClear

Legal and Registration

Standards and Governance

Domain Continuity